This phase II trial studies the safety and efficacy of aggressive thoracic radiotherapy in treating patients with non-small cell lung cancer that has not progressed after the first line systemic therapy. In this trial, patients with stage Ⅳ non small cell lung cancer who did not progress after first line systemic therapy will receive the aggressive thoracic radiotherapy, and the safety and efficacy of aggressive thoracic radiotherapy will be evaluated. The primary end points of the study are overall survival (OS), the secondary end points are local control rate, local progression free survival(LPFS), PFS, and toxicity and quality of life(QOL).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
Jiangmen central hospital
Jiangmen, Guangdong, China
RECRUITINGOS
overall survival
Time frame: two years after the beginning of first line systemic therapy
LPFS
local progression free survival
Time frame: 1 year after the beginning of first line systemic therapy
PFS
progression free survival
Time frame: 1 year after the beginning of first line systemic therapy
toxicity related to the radiotherapy
assess according to the National Cancer Institute-Common Terminology Criteria for Adverse Events 3.0
Time frame: from the beginning of radiotherapy to the 3 month after the completion of radiotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.